1Fischer JE,Funovies JM, Aguirre A, et al. The role of plasma amino acids in hepatic encephalopathy[J]. Surgery, 1975,78 (3) :276-290.
2Morgan MY, Milsom JP, Sherlock S. Plasma ratio of valine, leucine and isoleucine to phenylalanine and tyrosine in liver disease[J]. Gut,1978,19 (11) :1068-1073.
3AI Mardini H,Douglass A, Record C. Amino acid challenge in patients with cirrhosis and control subjects: ammonia, plasma amino acid and EEG changes[J]. Metab Brain Dis, 2006,21 (1) .. 1-10.
4Kano T,Nagaki M,Takahashi T,et al. Plasma free amino acid pattern in chronic hepatitis as a sensitive and prognostic index [J]. Gastroenterol Jpn, 1991,26(3) : 344-349.
5Azuma Y, Maekawa M, Kuwabara Y, et al. Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatie diseases, and its clinical usefulness[J]. Clin Chem, 1989,35(7) : 1399-1403.
6Sugiyama M, Kanno T, Ohkubo A, et al. The clinical usefulness of the molar ratio of branched-chain amino acids to tyrosine (BTR) in discriminating stage of chronic liver diseases[J]. Rinsho Byori, 1992,40(6) : 673-678.
7Suzuki K,Suzuki K,Koizumi K, et al. Measurement of serum branched-chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease[J]. Hepatol Res, 2008,38(3) : 267-272.
8Kohashi T, Itamoto T, Katayama K, et al. Significance of the molar ratio of branched-chain amino acids to tyrosine before hepatectomy[J]. Hepatogastroenterology, 2002,49 (45) : 774- 777.
9Vannueehi H, Marchini JS, Padovan GJ, et al. Amino acid patterns in the plasma and ascitic fluid of cirrhotic patients[J]. Braz J Med Biol Res,1985,18(4) :465-470.
5Mchutchison J, Poynard T, Afdhal N, et al. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibro- sis group. Clin Gastroenterol Hepatol, 2006, 4: 1214-1220.
6Rockey DC, Bissell M. Noninvasive measures of liver fibrosis. Hepatology, 2006, 43: s113-120.
7Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology, 2007, 45: 242-249.
8Powell EE, Edwards-Smith C J, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 2000,31: 828-833.
9Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology, 2006, 130: 1679-1687.
10Guha IN, Parkes J, Roderick PR, et al. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut, 2006, 55: 1650-1660.
1Fischer JE, Funovics JM, Aguirre A, et al. The role of plasma amino acids in hepatic encephalopathy. Surgery, 1975,78 : 276 -290.
2Morgan MY, Milsom JP, Sherlock S. Plasma ratio of valine, leucine and isoleucine to phenylalanine and tyrosine in liver disease. Gut, 1978,19:1068 -1073.
3Wai CT, Cheng CL, Wee A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int, 2006,26: 666-672.
4Shin WG, Park SH, Jang MK, et al. Asparate aminotransferase to platelet ration index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis, 2008,40 : 267-274.
5Morgan MY, Marshall AW, Milsom JP, et al. Plasma amino acid patterns in liver disease. Gut, 1982,23 : 362-370.
6Michitaka K, Hiraoka A, Kume M, et al. Amino acid imbalance in patients with chronic liver diseases. Hepatol Res, 2010,40:393-398.
7Kano T, Nagaki M, Takahashi T, et al. Plasma free amino acid pattern in chronic hepatitis as a sensitive and prognostic index. Gastroenterol Jpn, 1 991, 26 : 344-349.
8FISCHER JE, FUNOVICS JM, AGUIRRE, et al. The role of plasma a- mino acids in hepaticen cephalopathy [ J ]. Surgery, 1975,78 ( 3 ) : 276.
9MORGAN MY, MILSOM JP, SHERLOCK. Plasma ratio of valine, leu- cine and isoleucine to phenylalanine and tyrosne in liver disease[ J], Gut, 1978,19( 1 ) :1068.
10WAI, CHENG CL WEE A, et al. Non-invasive models for predicting his tology in patientswithchronichepatitis B [ J ]. Liver Int, 2006,26 (6) :666.
